BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27283831)

  • 1. Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.
    Yazdian-Robati R; Ramezani M; Jalalian SH; Abnous K; Taghdisi SM
    Pharm Res; 2016 Sep; 33(9):2289-97. PubMed ID: 27283831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
    Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
    Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
    Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
    Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo.
    Jalalian SH; Ramezani M; Abnous K; Taghdisi SM
    Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-targeted delivery system using hollow silica nanoparticles with H
    Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.
    Taghdisi SM; Danesh NM; Sarreshtehdar Emrani A; Tabrizian K; Zandkarimi M; Ramezani M; Abnous K
    J Drug Target; 2013 Sep; 21(8):739-44. PubMed ID: 23815443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of epirubicin to breast cancer cells using poly-aptamer DNA nanocarriers prepared by the RCA method with multiple repeats of aptamers of FOXM1 and AS1411.
    Moradi E; Zavvar T; Alibolandi M; Ramezani M; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2023 Mar; 49(3):260-270. PubMed ID: 37014177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
    Danesh NM; Lavaee P; Ramezani M; Abnous K; Taghdisi SM
    Int J Pharm; 2015 Jul; 489(1-2):311-7. PubMed ID: 25936625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Yazdian-Robati R; Abnous K
    Mol Pharm; 2018 May; 15(5):1972-1978. PubMed ID: 29669200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-targeting CD44 and mucin by hyaluronic acid and 5TR1 aptamer for epirubicin delivery into cancer cells: Synthesis, characterization,
    Jamshidi Z; Dehghan R; Nejabat M; Abnous K; Taghdisi SM; Hadizadeh F
    Heliyon; 2024 Jan; 10(2):e24833. PubMed ID: 38312665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles.
    Yazdian-Robati R; Bayat P; Dehestani S; Hashemi M; Taghdisi SM; Abnous K
    J Drug Target; 2022 Jun; 30(5):567-576. PubMed ID: 34991424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer.
    Alizadeh F; Yaghoobi E; Imanimoghadam M; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    J Drug Target; 2023 Dec; 31(9):986-997. PubMed ID: 37869893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
    Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
    Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.